CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 397 filers reported holding CRISPR THERAPEUTICS AG in Q4 2022. The put-call ratio across all filers is 0.90 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,458 | +23.2% | 76,178 | +52.4% | 0.24% | +29.3% |
| Q2 2023 | $2,807 | +228.3% | 49,998 | +164.5% | 0.18% | +211.9% |
| Q1 2023 | $855 | -99.6% | 18,904 | +512.8% | 0.06% | +268.8% |
| Q3 2022 | $202,000 | -31.3% | 3,085 | -34.1% | 0.02% | -11.1% |
| Q1 2022 | $294,000 | +35.5% | 4,680 | +63.4% | 0.02% | +50.0% |
| Q4 2021 | $217,000 | -28.1% | 2,865 | +6.1% | 0.01% | -33.3% |
| Q3 2021 | $302,000 | -28.4% | 2,700 | +3.6% | 0.02% | -30.8% |
| Q2 2021 | $422,000 | +40.7% | 2,605 | +5.9% | 0.03% | +30.0% |
| Q1 2021 | $300,000 | -19.8% | 2,460 | +0.8% | 0.02% | -23.1% |
| Q4 2020 | $374,000 | +79.8% | 2,440 | -2.0% | 0.03% | +62.5% |
| Q3 2020 | $208,000 | – | 2,490 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 508,558 | $82,330,000 | 27.28% |
| Valiant Capital Management, L.P. | 307,700 | $49,814,000 | 3.74% |
| NEA Management Company, LLC | 1,590,002 | $257,405,000 | 3.35% |
| NIA IMPACT ADVISORS, LLC | 39,891 | $6,458,000 | 3.15% |
| Ikarian Capital, LLC | 200,000 | $32,379,000 | 2.62% |
| Soleus Capital Management, L.P. | 103,114 | $16,693,000 | 2.57% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 157,334 | $25,471,000 | 2.47% |
| Capital Impact Advisors, LLC | 45,440 | $7,356,000 | 2.37% |
| ARK Investment Management | 7,776,119 | $1,258,876,000 | 2.34% |
| Sassicaia Capital Advisers LLC | 13,513 | $2,188,000 | 2.28% |